Oncolytics Biotech Inc. is focused on the development of oncolytic viruses for use as cancer therapeutics.
The Company’s lead product, REOLYSIN®, a proprietary formulation of the human reovirus, is currently entering into late stage (Phase III) clinical testing.
REOLYSIN® has been utilized in over thirty clinical trials including translational, Phase I, Phase II (single arm and randomized), and Phase III studies in a broad range of cancer indications.
REOLYSIN® is currently being manufactured at commercial scale in its final formulation under a commercial supply agreement with SAFC, a Division of Sigma-Aldrich® Fine Chemicals. Under the terms of the agreement, SAFC will manufacture all necessary product for clinical testing, as well as commercial product subject to the receipt of regulatory approval.
To date Oncolytics has been issued over four hundred patents worldwide, including the US and Canada, and has more than two hundred pending applications.